Sökning: (WFRF:(Tolmachev Vladimir Professor)) >
Evaluation of Appro...
-
Bragina, OlgaRussian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Dept Nucl Therapy & Diagnost, Tomsk 634014, Russia.;Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634009, Russia.,Department of Nuclear Therapy and Diagnostics, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634014, Russia; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634009, Russia;
(författare)
Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [99mTc]Tc-ADAPT6
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
MDPI,2024
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-528225
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-528225URI
-
https://doi.org/10.3390/pharmaceutics16040445DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-346389URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Corresponding author: Vladimir Tolmachev
-
QC 20240516
-
Due to its small size and high affinity binding, the engineered scaffold protein ADAPT6 is a promising targeting probe for radionuclide imaging of human epidermal growth factor receptor type 2 (HER2). In a Phase I clinical trial, [Tc-99m]Tc-ADAPT6 demonstrated safety, tolerability and capacity to visualize HER2 expression in primary breast cancer. In this study, we aimed to select the optimal parameters for distinguishing between breast cancers with high and low expression of HER2 using [Tc-99m]Tc-ADAPT6 in a planned Phase II study. HER2 expression was evaluated in primary tumours and metastatic axillary lymph nodes (mALNs). SPECT/CT imaging of twenty treatment-naive breast cancer patients was performed 2 h after injection of [Tc-99m]Tc-ADAPT6. The imaging data were compared with the data concerning HER2 expression obtained by immunohistochemical evaluation of samples obtained by core biopsy. Maximum Standard Uptake Values (SUVmax) afforded the best performance for both primary tumours and mALNs (areas under the receiver operating characteristic curve (ROC AUC) of 1.0 and 0.97, respectively). Lesion-to-spleen ratios provided somewhat lower performance. However, the ROC AUCs were still over 0.90 for both primary tumours and mALNs. Thus, lesion-to-spleen ratios should be further evaluated to find if these could be applied to imaging using stand-alone SPECT cameras that do not permit SUV calculations.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Tashireva, LiubovTomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634009, Russia.;Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Mol Canc Therapy, Tomsk 634014, Russia.;Tomsk Natl Res Med Ctr, Dept Gen & Mol Pathol, Tomsk 634014, Russia.,Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634009, Russia;; Laboratory of Molecular Cancer Therapy, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634014, Russia; Department of General and Molecular Pathology, Tomsk National Research Medical Center, Tomsk, 634014, Russia
(författare)
-
Loos, DmitriyTomsk Natl Res Med Ctr, Dept Gen & Mol Pathol, Tomsk 634014, Russia.,Department of General and Molecular Pathology, Tomsk National Research Medical Center, Tomsk, 634014, Russia
(författare)
-
Chernov, VladimirRussian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Dept Nucl Therapy & Diagnost, Tomsk 634014, Russia.;Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634009, Russia.,Department of Nuclear Therapy and Diagnostics, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634014, Russia; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634009, Russia;
(författare)
-
Hober, Sophia,Professor,1965-KTH,Proteinteknologi,KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, S-10044 Stockholm, Sweden.(Swepub:kth)u11qqzc1
(författare)
-
Tolmachev, VladimirUppsala universitet,Cancerprecisionsmedicin,Department of Immunology, Genetics and Pathology, Uppsala University, 751 81 Uppsala, Sweden(Swepub:uu)vladtolm
(författare)
-
Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Dept Nucl Therapy & Diagnost, Tomsk 634014, Russia.;Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634009, Russia.Department of Nuclear Therapy and Diagnostics, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634014, Russia; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634009, Russia;
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Pharmaceutics: MDPI16:41999-4923
Internetlänk
Hitta via bibliotek
Till lärosätets databas